The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Bykova O.V.

Research and Clinical Centre of Pediatric Psychoneurology Moscow Department of Public Health;
Medical Institute of the Peoples' Friendship University of Russia

Klimov Yu.A.

Scientific Practical Center of Pediatric Psychoneurology of the Department of Heath Care of Moscow;
Pirogov Russian National Research Medical UniversityResearch and Clinical Centre of Pediatric Psychoneurology Moscow Department of Public Health;
Medical Institute of the Peoples' Friendship University of Russia

Tikhonov S.V.

Research and Clinical Centre of Pediatric Psychoneurology Moscow Department of Public Health;
Medical Institute of the Peoples' Friendship University of Russia

Lalabekova M.V.

Research and Clinical Centre of Pediatric Psychoneurology Moscow Department of Public Health;
Medical Institute of the Peoples' Friendship University of Russia

Boyko E.A.

Scientific Practical Center of Pediatric Psychoneurology of the Department of Heath Care of Moscow

Batysheva T.T.

Research and Clinical Centre of Pediatric Psychoneurology Moscow Department of Public Health;
Medical Institute of the Peoples' Friendship University of Russia

Boyko A.N.

Scientific Practical Center of Pediatric Psychoneurology of the Department of Heath Care of Moscow;
Pirogov Russian National Research Medical University;
Federal Center of Brain Rresearch and Neurotechnologies of FMBA

Clinical observation experience of a pediatric patient with primary progressive multiple sclerosis in the Moscow office for the treatment of children and adolescents with multiple sclerosis

Authors:

Bykova O.V., Klimov Yu.A., Tikhonov S.V., Lalabekova M.V., Boyko E.A., Batysheva T.T., Boyko A.N.

More about the authors

Journal: S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(10): 45‑50

DOI: 10.17116/jnevro202012010145

Read: 2810 times

Download PDF (RU)
Contact the author
Table of contents

CLINICAL OBSERVATION EXPERIENCE OF A PEDIATRIC PATIENT WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS IN THE MOSCOW OFFICE FOR THE TREATMENT OF CHILDREN AND ADOLESCENTS WITH MULTIPLE SCLEROSIS
CLINICAL OBSERVATION EXPERIENCE OF A PEDIATRIC PATIENT WITH PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS IN THE MOSCOW OFFICE FOR THE TREATMENT OF CHILDREN AND ADOLESCENTS WITH MULTIPLE SCLEROSIS

To cite this article:

Bykova OV, Klimov YuA, Tikhonov SV, Lalabekova MV, Boyko EA, Batysheva TT, Boyko AN. Clinical observation experience of a pediatric patient with primary progressive multiple sclerosis in the Moscow office for the treatment of children and adolescents with multiple sclerosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2020;120(10):45‑50. (In Russ.)
https://doi.org/10.17116/jnevro202012010145

Подписка 2026 Журнал неврологии и психиатрии им. С.С. Корсакова (S.S. Korsakov Journal of Neurology and Psychiatry)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Current epidemiology of MS with onset in childhood and adolescence (pediatric multiple scle­rosis). S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):34-38
Features of the clinical course of multiple scle­rosis as a factor in persistent disa­bility. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):39-44
Resu­lts of 4 years of therapy with divo­zilimab in patients with rela­psing multiple scle­rosis. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(7-2):51-59
Abstract:

OBJECTIVE

To demonstrate the experience of a personalized approach to the treatment of pediatric patients with multiple sclerosis using the example of the Moscow patient population.

MATERIALS AND METHODS

The authors describe the clinical follow-up of 79 pediatric patients with demyelinating diseases of the nervous system during 2019, including 39 patients with multiple sclerosis, including one patient with a primary progressive course of the disease (clinical case).

RESULTS

The experience of the Moscow office for the treatment of multiple sclerosis in children and adolescents demonstrates the effectiveness of the personalized approach to the treatment of pediatric cases confirmed by the case report of biological therapy by recombinant humanized monoclonal antibody directed against CD20-expressing B-cells for early treatment of the adolescent patient with primary progressive multiple sclerosis.

CONCLUSION

The identification of patient’s groups with different levels of disease activity and different risks of disability progression is highly relevant in the pediatric population of patients with multiple sclerosis, especially in the context of expanding therapeutic opportunities.

Keywords:

pediatric multiple sclerosis
primary progressive course
monoclonal antibody
clinically isolated syndrome
active multiple sclerosis
disease modifying treatment (DMT)

Authors:

Bykova O.V.

Research and Clinical Centre of Pediatric Psychoneurology Moscow Department of Public Health;
Medical Institute of the Peoples' Friendship University of Russia

Klimov Yu.A.

Scientific Practical Center of Pediatric Psychoneurology of the Department of Heath Care of Moscow;
Pirogov Russian National Research Medical UniversityResearch and Clinical Centre of Pediatric Psychoneurology Moscow Department of Public Health;
Medical Institute of the Peoples' Friendship University of Russia

Tikhonov S.V.

Research and Clinical Centre of Pediatric Psychoneurology Moscow Department of Public Health;
Medical Institute of the Peoples' Friendship University of Russia

Lalabekova M.V.

Research and Clinical Centre of Pediatric Psychoneurology Moscow Department of Public Health;
Medical Institute of the Peoples' Friendship University of Russia

Boyko E.A.

Scientific Practical Center of Pediatric Psychoneurology of the Department of Heath Care of Moscow

Batysheva T.T.

Research and Clinical Centre of Pediatric Psychoneurology Moscow Department of Public Health;
Medical Institute of the Peoples' Friendship University of Russia

Boyko A.N.

Scientific Practical Center of Pediatric Psychoneurology of the Department of Heath Care of Moscow;
Pirogov Russian National Research Medical University;
Federal Center of Brain Rresearch and Neurotechnologies of FMBA

Received:

13.08.2020

Accepted:

08.10.2020

Close metadata

References:

  1. Boyko AN, Bykova OV, Sivertseva SA. Multiple sclerosis in children and adolescents (clinic, diagnosis, treatment). M.: MIA; 2016. (In Russ.).
  2. Mikaeloff Y, Suissa S, Vallee L, Lubetzki C, Ponsot G, Confavreux C, Tardieu M, KIDMUS Study Group. First episode of acute CNS inflammatory demyelination in childhood: prognostic factors for multiple sclerosis and disability. The Journal of Pediatrics. 2004;144:246-252.  https://doi.org/10.1016/j.jpeds.2003.10.056
  3. Banwell B, Ghezzi A, Bar-Or A, Mikaeloff Y, Tardieu M. Multiple sclerosis in children: clinical diagnosis, therapeutic strategies, and future directions. Lancet Neurology. 2007;6:887-902.  https://doi.org/10.1016/S1474-4422(07)70242-9
  4. Boyko A. Radiologically isolated syndrome with oligoclonal bands in CSF (RIS + OCB) can be classified as high MS risk group. Mult Scler. 2020;26(7):869-870.  https://doi.org/10.1177/1352458519879622
  5. Banwell B, Shroff M, Ness JM, Jeffery D, Schwid S, Weinstock-Guttman B. MRI features of pediatric multiple sclerosis. Neurology. 2007;68:46-53.  https://doi.org/10.1212/01.wnl.0000259406.09052.75
  6. Neuteboom RF, Boon M, Catsman Berrevoets CE, Vles JS, Gooskens RH, Stroink H, Vermeulen RJ, Rotteveel JJ, Ketelslegers IA, Peeters E, Poll-The BT, De Rijk-Van Andel JF, Verrips A, Hintzen RQ. Prognostic factors after a first attack of infl ammatory CNS demyelination in children. Neurology. 2008;71:967-973.  https://doi.org/10.1212/01.wnl.0000316193.89691.e1
  7. Boiko A, Vorobeychik G, Paty D, Devonshire V, Sadovnick D. University of British Columbia MS Clinic Neurologists. Early onset multiple sclerosis: a longitudinal study. Neurology. 2002;59:1006-1010. https://doi.org/10.1212/wnl.59.7.1006
  8. Boyko AN, Boyko OV, Gusev EI. Choosing the optimal drug for pathogenetic treatment of multiple sclerosis: current state of the problem. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2014;10(2):77-91. (In Russ.).
  9. Boyko AN, Gusev EI. Modern algorithms for the diagnosis and treatment of multiple sclerosis based on an individual assessment of the patient’s condition. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017;2(2):92-106. (In Russ.). https://doi.org/10.17116/jnevro20171172292-106
  10. Alifirova VM, Bakhtiyarova KZ, Belova AN, Bisaga GN, Boyko AN, Boyko OV, Vlasov YaV, Volkova LI, Goncharova ZA, Davydovskaya MV, Zakharova MN, Kotov SV, Lasch NYu, Malkova NA, Petrov AM, Popova EV, Sivertseva SA, Sokolova IA, Spirin NN, Stolyarov ID, Streknev AG, Totolyan NA, Khachanova NV, Sherman MI, Schmidt TE, Khabirov FA, Yampolskaya-Gosteva IA. Clinical recommendations for the use of Teriflunomide. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. Specvipuski. 2016;116(10):98-104. (In Russ.). https://doi.org/10.17116/jnevro201611610298-104
  11. Popova EV, Bryukhov VV, Boyko AN, Krotenkova MV. Primary progressive multiple sclerosis as an atypical demyelinating process. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2016;10(2):42-46. (In Russ.). https://doi.org/10.17116/jnevro201611610242-46
  12. Bittner S, Ruck T, Wiendl H, Grauer OM, Meuth SG. Targeting B cells in relapsing-remitting multiple sclerosis: from pathophysiology to optimal clinical management. Ther Adv Neurol Disord. 2017;10(1):51-66.  https://doi.org/10.1177/1756285616666741
  13. Hauser SL, Bar-Or A, Comi G, Comi G, Giovannoni G, Hartung H-P, Bernhard H, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS. OPERA I. and OPERA II Clinical Investigators. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017;376(3):221-234.  https://doi.org/10.1056/NEJMoa1601277
  14. Kappos L, Hauser SL, Montalban X, Craveiro L, Hughes R, Prajapati K, Pradhan A, Wormser D, Koendgen H, Wolinsky JS. Safety of ocrelizumab in multiple sclerosis: updated analysis in patients with relapsing and primary progressive multiple sclerosis. Presented at the 69th Annual Meeting in Boston, MA; April 22—28, 2017a. AAN Poster 407. 
  15. Kappos L, Li D, Calabresi PA, O’Connor P, Bar-Or A, Barkhof F, Yin M, Leppert D, Glanzman R, Tinbergen J, Hauser SL. Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: Week 144 results of a Phase II, randomised, multicentre trial. European Committee for Treatment & Research in Multiple Sclerosis — 28th Congress. 2012. Poster 362.  https://doi.org/10.1016/S0140-6736(11)61649-8
  16. Montalban X, Hauser SL, Kappos L, Douglas LA, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung H-P, Hemmer B, Lublin F, Rammohan KW, ORATORIO Clinical Investigators. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. N Engl J Med. 2017;376(3):209-220.  https://doi.org/10.1056/NEJMoa1606468
  17. Spirin NN, Boyko AN, Stepanov IO, Shmidt TE. Management of patients with multiple sclerosis. Methodical recommendation. M.: ROOI «Zdorov’e cheloveka»; 2015. (In Russ.).
  18. Khabirov FA, Khaybullin TI. Multiple sclerosis: modern principles of diagnosis and treatment. Monograph. Medicine; 2017. (In Russ.).
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.